Dr Khanani begins with the GALE study, which demonstrated that pegcetacoplan (PEG) provided benefit in visual function on a ...

A 36-week treatment regimen of pegcetacoplan reduces geographic atrophy growth rate while demonstrating a favorable safety profile.

Practice-changing studies in dry age-related macular degeneration (AMD) and promising new directions in wet AMD, presented at ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...

New advancements in Cold Agglutinin Disease treatments promise improved patient outcomes and market growth, driving innovation and investment in the sector.

Throughout the 26-week randomized, controlled treatment period, pegcetacoplan demonstrated favorable safety and tolerability. It also showed high compliance rates, consistent with its known profile.

Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still's ...

Shares of Apellis Pharmaceuticals ( APLS 2.47%) are down by about 62% from the peak they reached in January. However, investment bank analysts who follow the drugmaker think its best days are still ...

The endorsement follows the company's presentation at the American Society of Nephrology (ASN) where they shared additional Phase 3 data for their drug pegcetacoplan in the treatment of C3 ...